So, you have managed to shed 30 pounds with the help of one of the new blockbuster GLP-1 drugs, but as the holidays ...

The U.S. Food and Drug Administration has expanded the age indication for Nerivio, making it the first and only remote ...

Opioid use disorder (OUD) treatment continued to increase in intervention clinics in the third year of implementation ...

Menopausal hormone therapy (mHT) is not associated with long-term cognitive effects versus placebo, according to a stu ...

FRIDAY, Nov. 22, 2024 (HealthDay News) -- Diagnosis of postpartum depression increased significantly across all racial and ...

Younger and middle-aged patients seem to be disproportionately affected by neurologic manifestations of postacute sequ ...

An estimated 100,429 youth are living with pediatric inflammatory bowel disease (PIBD) in the United States, according ...

FRIDAY, Nov. 22, 2024 (HealthDay News) -- Semaglutide and liraglutide are associated with a reduced risk for hospitalization ...

An initial strategy of catheter ablation leads to a lower risk for a composite primary end point than antiarrhythmic d ...

Combination treatment with entinostat and nivolumab results in durable responses in a small subset of patients with ad ...

Recovery from anti-NMDA receptor (anti-NMDAR) encephalitis continues for three years, but deficits persist, according ...

More than half of all U.S. adults are eligible for semaglutide therapy, according to a research letter published onlin ...